Cargando…

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer

BACKGROUND: Advanced non-small-cell lung cancer (NSCLC) harbours many genetic aberrations that can be targeted with systemic treatments. Whole-genome sequencing (WGS) can simultaneously detect these (and possibly new) molecular targets. However, the exact added clinical value of WGS is unknown. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: Simons, Martijn J. H. G., Retèl, Valesca P., Ramaekers, Bram L. T., Butter, Rogier, Mankor, Joanne M., Paats, Marthe S., Aerts, Joachim G. J. V., Mfumbilwa, Zakile A., Roepman, Paul, Coupé, Veerle M. H., Uyl-de Groot, Carin A., van Harten, Wim H., Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599348/
https://www.ncbi.nlm.nih.gov/pubmed/34405371
http://dx.doi.org/10.1007/s40273-021-01073-y
_version_ 1784600929971994624
author Simons, Martijn J. H. G.
Retèl, Valesca P.
Ramaekers, Bram L. T.
Butter, Rogier
Mankor, Joanne M.
Paats, Marthe S.
Aerts, Joachim G. J. V.
Mfumbilwa, Zakile A.
Roepman, Paul
Coupé, Veerle M. H.
Uyl-de Groot, Carin A.
van Harten, Wim H.
Joore, Manuela A.
author_facet Simons, Martijn J. H. G.
Retèl, Valesca P.
Ramaekers, Bram L. T.
Butter, Rogier
Mankor, Joanne M.
Paats, Marthe S.
Aerts, Joachim G. J. V.
Mfumbilwa, Zakile A.
Roepman, Paul
Coupé, Veerle M. H.
Uyl-de Groot, Carin A.
van Harten, Wim H.
Joore, Manuela A.
author_sort Simons, Martijn J. H. G.
collection PubMed
description BACKGROUND: Advanced non-small-cell lung cancer (NSCLC) harbours many genetic aberrations that can be targeted with systemic treatments. Whole-genome sequencing (WGS) can simultaneously detect these (and possibly new) molecular targets. However, the exact added clinical value of WGS is unknown. OBJECTIVE: The objective of this study was to determine the early cost effectiveness of using WGS in diagnostic strategies compared with currently used molecular diagnostics for patients with inoperable stage IIIB,C/IV non-squamous NSCLC from a Dutch healthcare perspective. METHODS: A decision tree represented the diagnostic pathway, and a cohort state transition model represented disease progression. Three diagnostic strategies were modelled: standard of care (SoC) alone, WGS as a diagnostic test, and SoC followed by WGS. Treatment effectiveness was based on a systematic review. Probabilistic cost-effectiveness analyses were performed, and threshold analyses (using €80,000 per quality-adjusted life-year [QALY]) was used to explore the early cost effectiveness of WGS. RESULTS: WGS as a diagnostic test resulted in more QALYs (0.002) and costs (€1534 [incremental net monetary benefit –€1349]), and SoC followed by WGS resulted in fewer QALYs (–0.002) and more costs (€1059 [–€1194]) compared with SoC alone. WGS as a diagnostic test was only cost effective if it was priced at €2000 per patient and identified 2.7% more actionable patients than SoC alone. Treating these additional identified patients with new treatments costing >€4069 per month decreased the probability of cost effectiveness. CONCLUSIONS: Our analysis suggests that providing WGS as a diagnostic test is cost effective compared with SoC followed by WGS and SoC alone if costs for WGS decrease and additional patients with actionable targets are identified. This cost-effectiveness model can be used to incorporate new findings iteratively and to support ongoing decision making regarding the use of WGS in this rapidly evolving field. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01073-y.
format Online
Article
Text
id pubmed-8599348
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85993482021-11-24 Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer Simons, Martijn J. H. G. Retèl, Valesca P. Ramaekers, Bram L. T. Butter, Rogier Mankor, Joanne M. Paats, Marthe S. Aerts, Joachim G. J. V. Mfumbilwa, Zakile A. Roepman, Paul Coupé, Veerle M. H. Uyl-de Groot, Carin A. van Harten, Wim H. Joore, Manuela A. Pharmacoeconomics Original Research Article BACKGROUND: Advanced non-small-cell lung cancer (NSCLC) harbours many genetic aberrations that can be targeted with systemic treatments. Whole-genome sequencing (WGS) can simultaneously detect these (and possibly new) molecular targets. However, the exact added clinical value of WGS is unknown. OBJECTIVE: The objective of this study was to determine the early cost effectiveness of using WGS in diagnostic strategies compared with currently used molecular diagnostics for patients with inoperable stage IIIB,C/IV non-squamous NSCLC from a Dutch healthcare perspective. METHODS: A decision tree represented the diagnostic pathway, and a cohort state transition model represented disease progression. Three diagnostic strategies were modelled: standard of care (SoC) alone, WGS as a diagnostic test, and SoC followed by WGS. Treatment effectiveness was based on a systematic review. Probabilistic cost-effectiveness analyses were performed, and threshold analyses (using €80,000 per quality-adjusted life-year [QALY]) was used to explore the early cost effectiveness of WGS. RESULTS: WGS as a diagnostic test resulted in more QALYs (0.002) and costs (€1534 [incremental net monetary benefit –€1349]), and SoC followed by WGS resulted in fewer QALYs (–0.002) and more costs (€1059 [–€1194]) compared with SoC alone. WGS as a diagnostic test was only cost effective if it was priced at €2000 per patient and identified 2.7% more actionable patients than SoC alone. Treating these additional identified patients with new treatments costing >€4069 per month decreased the probability of cost effectiveness. CONCLUSIONS: Our analysis suggests that providing WGS as a diagnostic test is cost effective compared with SoC followed by WGS and SoC alone if costs for WGS decrease and additional patients with actionable targets are identified. This cost-effectiveness model can be used to incorporate new findings iteratively and to support ongoing decision making regarding the use of WGS in this rapidly evolving field. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01073-y. Springer International Publishing 2021-08-18 2021 /pmc/articles/PMC8599348/ /pubmed/34405371 http://dx.doi.org/10.1007/s40273-021-01073-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Simons, Martijn J. H. G.
Retèl, Valesca P.
Ramaekers, Bram L. T.
Butter, Rogier
Mankor, Joanne M.
Paats, Marthe S.
Aerts, Joachim G. J. V.
Mfumbilwa, Zakile A.
Roepman, Paul
Coupé, Veerle M. H.
Uyl-de Groot, Carin A.
van Harten, Wim H.
Joore, Manuela A.
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
title Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
title_full Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
title_fullStr Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
title_full_unstemmed Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
title_short Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
title_sort early cost effectiveness of whole-genome sequencing as a clinical diagnostic test for patients with inoperable stage iiib,c/iv non-squamous non-small-cell lung cancer
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599348/
https://www.ncbi.nlm.nih.gov/pubmed/34405371
http://dx.doi.org/10.1007/s40273-021-01073-y
work_keys_str_mv AT simonsmartijnjhg earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT retelvalescap earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT ramaekersbramlt earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT butterrogier earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT mankorjoannem earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT paatsmarthes earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT aertsjoachimgjv earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT mfumbilwazakilea earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT roepmanpaul earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT coupeveerlemh earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT uyldegrootcarina earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT vanhartenwimh earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer
AT jooremanuelaa earlycosteffectivenessofwholegenomesequencingasaclinicaldiagnostictestforpatientswithinoperablestageiiibcivnonsquamousnonsmallcelllungcancer